A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation

Trial Title: A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation

NCT ID: NCT06081829

Condition: Cholangiocarcinoma Non-resectable
Cholangiocarcinoma Metastatic

Conditions: Official terms:
Cholangiocarcinoma
Ivosidenib

Conditions: Keywords:
IDH-1 Mutation
Cholangiocarcinoma Non-resectable with an IDH-1 Mutation
Cholangiocarcinoma Metastatic with an IDH-1 Mutation

Study type: Interventional

Study phase: Phase 2

Overall status: Active, not recruiting

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: Ivosidenib
Description: Subjects will take 2 tablets (500 mg total) orally once daily.
Arm group label: Open-Label Ivosidenib

Summary: This study will enroll participants with nonresectable or metastatic cholangiocarcinoma with an Isocitrate dehydrogenase protein, 1 (IDH1) mutation, who have previously received at least 1, but no more than 2, prior regimens for advanced disease. All participants will receive ivosidenib daily throughout multiple 28 day cycles. Study treatment will be administered until participant experiences unacceptable toxicity, disease progression, or other discontinuation criteria are met. Study visits will be conducted every week during Cycle 1 (Days 1, 8, 15, and 22), every other week during Cycles 2 and 3, and Day 1 of each cycle thereafter. After the last dose of treatment, participants will attend an end of treatment and a post-treatment follow-up visit, and participants will be followed to assess overall survival. Study visits may include a tumor assessment, physical exam, electrocardiogram (ECG), blood and urine analysis, and questionnaires.

Criteria for eligibility:
Criteria:
Inclusion Criteria: - Have nonresectable or metastatic cholangiocarcinoma and are not eligible for curative resection, transplantation or ablative therapies - Have documented IDH1 gene-mutated disease from a tumor biopsy - Have an ECOG PS score of 0 or 1 - Have an expected survival of 3 months or more - Have at least one evaluable and measurable lesion - Have disease progression following the most recent of 1 or 2 prior systemic regimens for advanced disease with progression on the treatment that was most recently given at a minimum, and must have received at least 1 gemcitabine- or 5-FU -containing regimen - Have recovered from side effects associated with the prior treatment therapy - Have adequate bone marrow function - Have adequate hepatic (liver) and renal (kidney) function - Women of child bearing potential must have a negative serum pregnancy test before starting study treatment, and use birth control during the study and for 90 days after the last dose of ivosidenib - Fertile men with female partners of child bearing potential must use birth control during the study and for 90 days after the last dose of ivosidenib Exclusion Criteria: - Received a prior IDH inhibitor. - Have known symptomatic brain metastases requiring steroids. - Pregnancy, possibility of becoming pregnant during the study and breast-feeding women or woman who plans to restart breast-feeding after the study drug administration/intake. - Are taking known strong cytochrome P450 (CYP) 3A4 inducers or sensitive CYP3A4 substrate medications with a narrow therapeutic window - Have significant heart disease, including congestive heart failure, myocardial infarction (heart attack) unstable angina (chest pain) and/or stroke, within 6 months before starting the study - Have a heart-rate corrected QT interval ≥450 msec or other factors that increase the risk of QT prolongation or arrhythmic events - . Have active inflammatory gastrointestinal disease, chronic diarrhea, previous gastric resection or lap band dysphagia, short-gut syndrome, gastroparesis (paralysis of the stomach), or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally. - Have known medical history of progressive multifocal leukoencephalopathy (PML)

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: National Cancer Center Hospital East (JPN-002)

Address:
City: Kashiwa
Zip: 277-8577
Country: Japan

Facility:
Name: Kumamoto University Hospital (JPN-004)

Address:
City: Kumamoto
Zip: 860-8556
Country: Japan

Facility:
Name: National Hospital Organization Shikoku Cancer Center (JPN-007)

Address:
City: Matsuyama
Zip: 791-0280
Country: Japan

Facility:
Name: Osaka International Cancer Institute (JPN-005)

Address:
City: Osaka
Zip: 541-8567
Country: Japan

Facility:
Name: Hokkaido University Hospital (JPN-006)

Address:
City: Sapporo
Zip: 060-8648
Country: Japan

Facility:
Name: National Cancer Center Hospital (JPN-001)

Address:
City: Tokyo
Country: Japan

Facility:
Name: Kanagawa Cancer Center (JPN-003)

Address:
City: Yokohama
Zip: 241-8515
Country: Japan

Start date: October 10, 2023

Completion date: May 2027

Lead sponsor:
Agency: Servier
Agency class: Industry

Source: Servier

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT06081829